GeneDx Holdings Corp. Class A WGS
NASDAQ · United States · Health Services
$72.30-3.49 (-4.60%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Key Takeaways:Record Testing Volume: GeneDx delivered over 30,000 exome and genome tests in Q2, up 32% year-over-year, and returned to profitability a quarter ahead of schedule. Price Projection: Based on current assumptions, WGS stock could reach $137 by December 2028.
GAITHERSBURG, Md., September 09, 2026--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
GAITHERSBURG, Md., September 01, 2026--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.